- Home
- SNY vs FINW Comparison
SNY vs FINW Comparison
Compare SNY & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- FINW
- Stock Information
- Founded
- SNY 1994
- FINW 1999
- Country
- SNY France
- FINW United States
- Employees
- SNY N/A
- FINW N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- SNY Health Care
- FINW Finance
- Exchange
- SNY Nasdaq
- FINW Nasdaq
- Market Cap
- SNY 113.4B
- FINW 261.6M
- IPO Year
- SNY N/A
- FINW 2021
- Fundamental
- Price
- SNY $47.59
- FINW $20.49
- Analyst Decision
- SNY Buy
- FINW Buy
- Analyst Count
- SNY 4
- FINW 4
- Target Price
- SNY $61.50
- FINW $20.75
- AVG Volume (30 Days)
- SNY 2.7M
- FINW 11.1K
- Earning Date
- SNY 10-24-2025
- FINW 10-23-2025
- Dividend Yield
- SNY 3.40%
- FINW N/A
- EPS Growth
- SNY 118.56
- FINW N/A
- EPS
- SNY 8.65
- FINW 0.96
- Revenue
- SNY $53,714,621,258.00
- FINW $74,999,000.00
- Revenue This Year
- SNY $1.53
- FINW $52.89
- Revenue Next Year
- SNY $7.06
- FINW $20.66
- P/E Ratio
- SNY $5.43
- FINW $20.45
- Revenue Growth
- SNY 15.65
- FINW 10.21
- 52 Week Low
- SNY $44.73
- FINW $13.49
- 52 Week High
- SNY $60.12
- FINW $20.94
- Technical
- Relative Strength Index (RSI)
- SNY 47.18
- FINW 65.29
- Support Level
- SNY $46.50
- FINW $19.00
- Resistance Level
- SNY $47.69
- FINW $19.79
- Average True Range (ATR)
- SNY 0.69
- FINW 0.60
- MACD
- SNY -0.10
- FINW -0.02
- Stochastic Oscillator
- SNY 47.94
- FINW 82.23
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.